Brodalumab

Siliq

210 MG / 1.5 ML SolutionCanadaMarketedAuthorised 5 Jul 2018

In other countries

The same active substances on other registers, the same brand first.

SiliqUnited States · 210MG/1.5ML · injectable · Valeant LuxembourgSame brand
KyntheumBrazil · Leo Pharma LtdaSame substance
Kyntheum 210 MG Solucion Inyectable en Jeringa PrecargadaSpain · 210 mg · solución inyectable · Leo Pharma A/SSame substance
KyntheumEuropean Union · LEO Pharma A/SSame substance
KyntheumCroatiaSame substance
KyntheumItaly · Soluzione iniettabile · Leo Pharma A/SSame substance
Kyntheum 210 mg, oplossing voor injectie in voorgevulde spuitNetherlands · Oplossing voor injectie · AstraZeneca UK LimitedSame substance

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Brodalumab

Siliq

210 MG / 1.5 ML SolutionCanadaMarketedAuthorised 5 Jul 2018

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

LUMICEF Subcutaneous Injection 210mg SyringeTaiwan · 注射液劑 · 台灣大昌華嘉股份有限公司

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Brodalumab
Strength: 210 MG / 1.5 ML
Dosage form: Solution
Route: Subcutaneous
Register: Canada (Health Canada)
Status: Marketed
Authorised: 5 Jul 2018
Registration: DIN 02473623
Marketing authorisation holder: Bausch Health, Canada INC.
ATC code: L04AC12
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION, SCHEDULE D